Boston Scientific (BSX) Stock Price

Boston Scientific Price

🇺🇸NYSE·CLOSED
48.42USD
Market closed
Today +/-
Today %

Boston Scientific (BSX) Stock | ISIN US1011371077 | WKN 884113. The current Boston Scientific stock price is 48.42 USD (2026). Revenue is 22.49 B USD. Net income is 5.19 B USD. The P/E ratio is 13.93. Market capitalization is 71.81 B USD. Boston Scientific operates in the Health sector.

Boston Scientific stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Boston Scientific over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Boston Scientific stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Boston Scientific's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Boston Scientific Stock Price History
DateBoston Scientific Price
Access this data via the Eulerpool API

Boston Scientific Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
7.82 B USD
1.23 B USD
-3.58 B USD
Jan 1, 2007
8.36 B USD
1.19 B USD
-495 M USD
Jan 1, 2008
8.05 B USD
1.27 B USD
-2.04 B USD
Jan 1, 2009
8.19 B USD
1.25 B USD
-1.03 B USD
Jan 1, 2010
7.81 B USD
993 M USD
-1.07 B USD
Jan 1, 2011
7.62 B USD
1.02 B USD
441 M USD
Jan 1, 2012
7.25 B USD
961 M USD
-4.07 B USD
Jan 1, 2013
7.14 B USD
903 M USD
-121 M USD
Jan 1, 2014
7.38 B USD
1.04 B USD
-119 M USD
Jan 1, 2015
7.48 B USD
924 M USD
-239 M USD
Jan 1, 2016
8.39 B USD
1.34 B USD
347 M USD
Jan 1, 2017
9.05 B USD
1.67 B USD
104 M USD
Jan 1, 2018
9.82 B USD
1.74 B USD
1.67 B USD
Jan 1, 2019
10.74 B USD
1.82 B USD
4.7 B USD
Jan 1, 2020
9.91 B USD
902 M USD
-115 M USD

Boston Scientific Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 11, 2026, 7:11 AM
 
REVENUE (M USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Boston Scientific generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Boston Scientific retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Boston Scientific's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Boston Scientific has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Boston Scientific's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Boston Scientific stock margins

The Boston Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boston Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boston Scientific.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
68.83 %
15.68 %
-45.74 %
Jan 1, 2007
69.56 %
14.28 %
-5.92 %
Jan 1, 2008
66.81 %
15.79 %
-25.29 %
Jan 1, 2009
66.21 %
15.32 %
-12.52 %
Jan 1, 2010
64.34 %
12.72 %
-13.64 %
Jan 1, 2011
63.25 %
13.33 %
5.79 %
Jan 1, 2012
65.6 %
13.26 %
-56.12 %
Jan 1, 2013
67.6 %
12.64 %
-1.69 %
Jan 1, 2014
68.88 %
14.02 %
-1.61 %
Jan 1, 2015
70.42 %
12.36 %
-3.2 %
Jan 1, 2016
70.56 %
15.98 %
4.14 %
Jan 1, 2017
71.09 %
18.45 %
1.15 %
Jan 1, 2018
71.13 %
17.7 %
17.01 %
Jan 1, 2019
70.67 %
16.96 %
43.78 %
Jan 1, 2020
65.24 %
9.1 %
-1.16 %

Boston Scientific Stock Revenue, EBIT, Earnings per Share

The Boston Scientific earnings per share therefore indicates how much revenue Boston Scientific has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
6.14 USD
0.96 USD
-2.81 USD
Jan 1, 2007
5.62 USD
0.8 USD
-0.33 USD
Jan 1, 2008
5.37 USD
0.85 USD
-1.36 USD
Jan 1, 2009
5.43 USD
0.83 USD
-0.68 USD
Jan 1, 2010
5.14 USD
0.65 USD
-0.7 USD
Jan 1, 2011
5.02 USD
0.67 USD
0.29 USD
Jan 1, 2012
5.15 USD
0.68 USD
-2.89 USD
Jan 1, 2013
5.33 USD
0.67 USD
-0.09 USD
Jan 1, 2014
5.57 USD
0.78 USD
-0.09 USD
Jan 1, 2015
5.57 USD
0.69 USD
-0.18 USD
Jan 1, 2016
6.09 USD
0.97 USD
0.25 USD
Jan 1, 2017
6.5 USD
1.2 USD
0.07 USD
Jan 1, 2018
7.01 USD
1.24 USD
1.19 USD
Jan 1, 2019
7.61 USD
1.29 USD
3.33 USD
Jan 1, 2020
7 USD
0.64 USD
-0.08 USD

Boston Scientific business model & stock analysis

Boston Scientific Corp. is a global medical technology company specializing in the development and manufacturing of innovative solutions for medical challenges and needs. The company was founded in 1979 and has since been dedicated to meeting the individual needs of patients and medical professionals with innovative products. The history of Boston Scientific began in the 1960s when French engineer Jean-Marc Simon started developing pacemakers at the University of Minnesota. In 1969, Medtronic acquired Simon's pacemaker development, leading to the founding of Boston Scientific. From the beginning, the company focused on the production of cardiovascular implants, including pacemakers, implanted defibrillators, and stents. In the following years, the company achieved continued growth through acquisitions of competitors and advancements in research and development, particularly in the field of minimally invasive procedures. Today, Boston Scientific is a globally leading provider of innovative medical devices and solutions used in various areas of healthcare. Boston Scientific's business model is based on meeting the needs of patients, medical professionals, and healthcare policymakers in order to improve healthcare. The company works closely with doctors, hospitals, nursing facilities, and research institutions to continuously develop innovative solutions for various diseases and conditions. Boston Scientific has five business segments: Cardiovascular Systems, Interventional Oncology and Neuromodulation, Urology and Women's Health, Medical Oncology, and Endoscopy. The Cardiovascular Systems segment includes products and solutions for cardiovascular surgery, including pacemakers, implanted defibrillators, and catheters. The company is also involved in endovascular surgery, offering innovative stent and catheter systems for the treatment of aneurysms and arterial occlusive disease. The Interventional Oncology and Neuromodulation segment includes solutions for the minimally invasive treatment of cancer and chronic pain through catheter and implant systems. For example, Boston Scientific offers intensity-controlled radiofrequency ablation and neuromodulation procedures. The Urology and Women's Health segment includes products for the treatment and diagnosis of urogenital system disorders, including incontinence, urinary incontinence, and genital diseases. Boston Scientific offers innovative solutions for women, such as the treatment of urinary incontinence or the removal of uterine fibroids. The Medical Oncology segment includes products for the diagnosis and treatment of cancer, including in vitro diagnostics and novel treatments such as chemotherapy delivery technology. The Endoscopy segment includes endoscopic solutions, including the diagnosis and therapy of digestive tract, chest, and lung disorders. Boston Scientific's product portfolio is diverse and includes numerous innovative medical devices and systems designed to meet the needs of patients and medical professionals. Some of the notable products of the company include: - The Implantable Cardioverter-Defibrillator (ICD) is an innovative device that can treat heart rhythm disorders through the use of a remote control. - Drug-Eluting Stents are stents that deliver medication directly at the site of narrowing, promoting blood flow and helping to keep the artery open. - The Synergy is a top-of-the-line stent that has both a lower mortality rate and a higher success rate than conventional stents. - The Venus-EP Steerable Sheath is an advanced catheter that allows physicians unique navigation within the heart chambers. - The Precision is a catheter that sends impulses to the heart for the diagnosis and treatment of atrial fibrillation. - The Transcend is a pacemaker that combines traditional pacemaker function with a sensor that actively supports the patient during physical activity. - The Symphion is an innovative system for laparoscopic surgery that enables minimally invasive surgical procedures in women. In conclusion, Boston Scientific Corp. is a globally leading provider of innovative medical devices and solutions that run like a common thread through its various business segments. With a significant focus on research and development, the company offers a wide range of products to ensure that patients worldwide have access to innovative medical care. Through pioneering innovations, the development of new technologies, and collaboration with medical professionals, Boston Scientific will continue to defend its position as a leading provider of medical solutions worldwide.

Boston Scientific SWOT Analysis

Strengths

Boston Scientific Corp has a strong portfolio of innovative medical devices and technologies that cater to a wide range of medical specialties.

The company has a global presence and operates in over 130 countries, providing access to a large customer base and potential for market expansion.

Boston Scientific Corp has a solid reputation for delivering high-quality products and services, leading to strong customer loyalty and trust.

Weaknesses

One of the weaknesses for Boston Scientific Corp is its dependence on third-party suppliers for certain critical components, which makes the company vulnerable to supply chain disruptions.

The company has faced challenges related to regulatory compliance, which can impact its ability to introduce new products and comply with changing market requirements.

Boston Scientific Corp operates in a highly competitive market, which puts pressure on pricing and profit margins.

Opportunities

The growing global healthcare market presents opportunities for Boston Scientific Corp to expand its customer base and increase sales.

Advancements in medical technology and increased adoption of minimally invasive procedures create opportunities for the company to develop and introduce new innovative products.

Expansion into emerging markets, such as Asia and Latin America, offers the potential for significant revenue growth for Boston Scientific Corp.

Threats

Intense competition from other medical device companies poses a threat to Boston Scientific Corp's market share and profitability.

Changes in healthcare regulations and policies can impact the pricing and reimbursement of medical devices, posing challenges to the company's financial performance.

Fluctuating currency exchange rates can affect Boston Scientific Corp's international operations and profitability.

Boston Scientific Segments

Boston Scientific Revenue by Segment (1/6)

  • 3 Years

  • 5 Years

  • Max

Global Cardiology Reporting Unit
Global Interventional Cardiology (IC) Reporting Unit
Interventional Cardiology Therapies
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Watchman
Global Neuromodulation (NM) Reporting Unit
Electrophysiology (EP)
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
BTG Spec Pharma
Details
Date
Global Cardiology Reporting Unit
Global Interventional Cardiology (IC) Reporting Unit
Interventional Cardiology Therapies
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Watchman
Global Neuromodulation (NM) Reporting Unit
Electrophysiology (EP)
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
BTG Spec Pharma
Other
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
2.82 B USD
0 USD
1.89 B USD
0 USD
1.94 B USD
1.39 B USD
1.41 B USD
0 USD
873 M USD
0 USD
329 M USD
0 USD
11 M USD
0 USD
Jan 1, 2020
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
13 M USD
0 USD
0 USD
Jan 1, 2022
5.93 B USD
0 USD
2.23 B USD
2.22 B USD
2.1 B USD
0 USD
1.9 B USD
1.77 B USD
1.02 B USD
917 M USD
585 M USD
0 USD
0 USD
0 USD
0 USD

Boston Scientific Revenue by Segment (2/6)

  • 3 Years

  • Max

Other
Details
Date
Other
Jan 1, 2010
0 USD
Jan 1, 2014
0 USD
Jan 1, 2015
0 USD
Jan 1, 2016
0 USD
Jan 1, 2019
0 USD
Jan 1, 2020
0 USD
Jan 1, 2021
0 USD
Jan 1, 2022
-60 M USD

Boston Scientific Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • Max

Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
Details
Date
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2020
2.3 B USD
1.78 B USD
1.7 B USD
1.58 B USD
1.29 B USD
761 M USD
287 M USD
219 M USD
Jan 1, 2021
3.04 B USD
2.14 B USD
2.02 B USD
1.82 B USD
1.58 B USD
909 M USD
365 M USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD

Boston Scientific Revenue by Segment (4/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

BSX Reportable Segments
Cardiovascular
MedSurg
Rhythm and Neuro
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology (Uro) Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Details
Date
BSX Reportable Segments
Cardiovascular
MedSurg
Rhythm and Neuro
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global Peripheral Interventions (PI) Reporting Unit
Endoscopy
Global Urology (Uro) Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Urology Women's/Health
Neurovascular
Neuromodulation
Electrophysiology
Jan 1, 2010
0 USD
3.27 B USD
0 USD
0 USD
0 USD
0 USD
2.18 B USD
0 USD
1.08 B USD
0 USD
0 USD
481 M USD
340 M USD
304 M USD
147 M USD
Jan 1, 2014
0 USD
0 USD
0 USD
0 USD
2.09 B USD
1.34 B USD
0 USD
861 M USD
0 USD
542 M USD
474 M USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
0 USD
2.24 B USD
1.42 B USD
0 USD
975 M USD
0 USD
735 M USD
512 M USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
0 USD
2.52 B USD
1.57 B USD
0 USD
1.09 B USD
0 USD
1.07 B USD
574 M USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2019
10.65 B USD
0 USD
3.31 B USD
3.14 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2020
0 USD
3.88 B USD
3.07 B USD
2.75 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
4.86 B USD
3.72 B USD
3.29 B USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD

Boston Scientific Revenue by Segment (5/6)

  • 3 Years

  • 5 Years

  • Max

BSX Reportable Segments
Cardiovascular
MedSurg
Details
Date
BSX Reportable Segments
Cardiovascular
MedSurg
Jan 1, 2010
0 USD
0 USD
0 USD
Jan 1, 2014
0 USD
0 USD
0 USD
Jan 1, 2015
0 USD
0 USD
0 USD
Jan 1, 2016
0 USD
0 USD
0 USD
Jan 1, 2019
0 USD
0 USD
0 USD
Jan 1, 2020
9.69 B USD
0 USD
0 USD
Jan 1, 2021
11.88 B USD
0 USD
0 USD
Jan 1, 2022
0 USD
7.83 B USD
4.91 B USD

Boston Scientific Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Cardiovascular
MedSurg
Rhythm Management
Global CRM Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Other Segments
Details
Date
Cardiovascular
MedSurg
Rhythm Management
Global CRM Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Other Segments
Jan 1, 2010
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2014
2.95 B USD
2.36 B USD
2.15 B USD
1.92 B USD
228 M USD
0 USD
Jan 1, 2015
3.22 B USD
2.67 B USD
2.18 B USD
1.93 B USD
248 M USD
0 USD
Jan 1, 2016
3.62 B USD
3.2 B USD
2.26 B USD
1.99 B USD
261 M USD
0 USD
Jan 1, 2019
4.21 B USD
0 USD
0 USD
0 USD
0 USD
81 M USD
Jan 1, 2020
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2021
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD
Jan 1, 2022
0 USD
0 USD
0 USD
0 USD
0 USD
0 USD

Boston Scientific Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
country_US excluding Other Net Sales
Int'l
Other Countries
Europe, Middle East and Africa
EMEA
Asia-Pacific
Emerging Markets
APAC
Asia Pacific
Latin America and Canada
Details
Date
United States
country_US excluding Other Net Sales
Int'l
Other Countries
Europe, Middle East and Africa
EMEA
Asia-Pacific
Emerging Markets
APAC
Asia Pacific
Latin America and Canada
Jan 1, 2018
5.54 B USD
0 USD
0 USD
4.29 B USD
0 USD
2.18 B USD
0 USD
1.07 B USD
0 USD
1.73 B USD
383 M USD
Jan 1, 2019
6.1 B USD
0 USD
0 USD
4.57 B USD
0 USD
2.26 B USD
0 USD
1.25 B USD
0 USD
1.9 B USD
395 M USD
Jan 1, 2020
5.51 B USD
0 USD
0 USD
4.21 B USD
0 USD
2.1 B USD
0 USD
1.09 B USD
1.78 B USD
0 USD
307 M USD
Jan 1, 2021
6.9 B USD
0 USD
0 USD
4.98 B USD
0 USD
2.52 B USD
0 USD
1.43 B USD
2.07 B USD
0 USD
386 M USD
Jan 1, 2022
7.63 B USD
7.63 B USD
0 USD
5.11 B USD
0 USD
2.53 B USD
0 USD
1.72 B USD
2.12 B USD
0 USD
469 M USD
Jan 1, 2023
8.43 B USD
8.43 B USD
0 USD
5.82 B USD
0 USD
2.86 B USD
0 USD
2.31 B USD
2.4 B USD
0 USD
560 M USD
Jan 1, 2024
10.21 B USD
10.21 B USD
0 USD
6.54 B USD
0 USD
3.23 B USD
0 USD
2.68 B USD
2.69 B USD
0 USD
624 M USD
Jan 1, 2025
12.86 B USD
0 USD
7.21 B USD
0 USD
3.45 B USD
0 USD
3.08 B USD
2.99 B USD
0 USD
0 USD
678 M USD

Boston Scientific Eulerpool Fair Value

Boston Scientific historical P/E ratio, EBIT multiple, and P/S ratio

Boston Scientific annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Boston Scientific shares outstanding

The number of shares was Boston Scientific in 2025 — This indicates how many shares 1.495 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
1.27 B base_Shares
Jan 1, 2007
1.49 B base_Shares
Jan 1, 2008
1.5 B base_Shares
Jan 1, 2009
1.51 B base_Shares
Jan 1, 2010
1.52 B base_Shares
Jan 1, 2011
1.52 B base_Shares
Jan 1, 2012
1.41 B base_Shares
Jan 1, 2013
1.34 B base_Shares
Jan 1, 2014
1.32 B base_Shares
Jan 1, 2015
1.34 B base_Shares
Jan 1, 2016
1.38 B base_Shares
Jan 1, 2017
1.39 B base_Shares
Jan 1, 2018
1.4 B base_Shares
Jan 1, 2019
1.41 B base_Shares
Jan 1, 2020
1.42 B base_Shares
Price targets and forecasts for Boston Scientific are not yet available.

Boston Scientific Earnings Estimates

Boston Scientific Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/22/20260.8USD5.22 BUSD2026 Q1
2/4/20260.79USD5.33 BUSD2025 Q4
4/24/20240.52USD3.7 BUSD2024 Q1
1/30/20240.52USD3.63 BUSD2023 Q4
7/25/20230.49USD3.47 BUSD2023 Q2
4/25/20230.45USD3.22 BUSD2023 Q1
1/31/20230.48USD3.29 BUSD2022 Q4
10/26/20220.45USD3.18 BUSD2022 Q3
7/27/20220.43USD3.26 BUSD2022 Q2
4/27/20220.39USD3 BUSD2022 Q1
...

EESG©

Eulerpool ESG Scorecard© for the Boston Scientific stock

71/100
56
Environment
94
Social
63
Governance
E

Environment

20
Scope 1 - Direct Emissions87,567
Scope 2 - Indirect emissions from purchased energy112,861
Scope 3 - Indirect emissions within the value chain2,035,890
Total CO₂ emissions200,429
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49.9
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees61
White Management Share77.8
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Boston Scientific shareholder structure

% Name
9.2025%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.70746%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
5.27204%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.39589%
State Street Investment Management (US)
State Street Investment Management (US)
2.33731%
PRIMECAP Management Company
PRIMECAP Management Company
2.20155%
Wellington Management Company, LLP
Wellington Management Company, LLP
2.18642%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.92342%
Capital World Investors
Capital World Investors
1.487%
Managed Account Advisors LLC
Managed Account Advisors LLC
1.35396%
The Bollard Group, LLC
The Bollard Group, LLC
...

Boston Scientific Executives and Management Board

MM

Mr. Michael Mahoney

(60)

Chairman of the Board, President, Chief Executive Officer · since 2011

Compensation21.42 M USD
JF

Mr. Joseph Fitzgerald

(61)

Executive Vice President, Group President - Cardiology

Compensation6.34 M USD
AB

Mr. Arthur Butcher

(54)

Executive Vice President, Group President, MedSurg and Asia Pacific

Compensation5.01 M USD
JM

Mr. Jeffrey Mirviss

(59)

Executive Vice President and President - Peripheral Interventions

Compensation4.03 M USD
EL

Mr. Edward Ludwig

(73)

Lead Independent Director

Compensation376,667 USD

Boston Scientific Supply Chain

Frequently asked questions about Boston Scientific

The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.

All fundamentals and in-depth analysis of Boston Scientific

Our stock analysis for Boston Scientific Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boston Scientific Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.